Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug:77:100739.
doi: 10.1016/j.jbior.2020.100739. Epub 2020 Jun 26.

Cancer therapy and treatments during COVID-19 era

Shaw M Akula  1 , Stephen L Abrams  1 , Linda S Steelman  1 , Saverio Candido  2 , Massimo Libra  2 , Kvin Lerpiriyapong  3 , Lucio Cocco  4 , Giulia Ramazzotti  4 , Stefano Ratti  4 , Matilde Y Follo  4 , Alberto M Martelli  4 , William L Blalock  5 , Manuela Piazzi  5 , Giuseppe Montalto  6 , Melchiorre Cervello  7 , Monica Notarbartolo  8 , Jorg Basecke  9 , James A McCubrey  10
Affiliations
Review

Cancer therapy and treatments during COVID-19 era

Shaw M Akula et al. Adv Biol Regul. 2020 Aug.

Abstract

The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disease progression. This review article will summarize how the treatments of various cancer patients has changed during the COVID-19 era as well as discuss the promise of some existing drugs and other agents to be repurposed to treat this disease.

Keywords: COVID-19; Cancer; Natural products; Nutraceuticals; Repurposing approved drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest with publication of this manuscript.

Figures

Fig. 1
Fig. 1
Overview of the symptoms and diagnosis of COVID-19 disesase.
Fig. 2
Fig. 2
Overview of Some of the Factors which May Influence the Development of COVID-19 Disease.
Fig. 3
Fig. 3
Overview of potential sites of therapeutic intervention in COVID-19 disease.
See this image and copyright information in PMC

References

    1. Baumann B.C., MacArthur K.M., Brewer J.D., Mendenhall W.M., Barker C.A., Etzkorn J.R., Jellinek N.J., Scott J.F., Gay H.A., Baumann J.C., Manian F.A., Devlin P.M., Michalski J.M., Lee N Y., Thorstad W.L., Wilson L.D., Perez C.A., Miller C.J. Management of primary skin cancer during a pandemic: multidisciplinary recommendations. Cancer. 2020 2020 Jun 01. - PMC - PubMed
    1. Bernhardt D., Wick W., Weiss S.E., Sahgal A., Lo S.S., Suh J.H., Chang E.L., Foote M., Perry J., Meyer B., Vajkoczy P., Wen P.Y., Straube C., Pigorsch S., Wilkens J.J., Combs S.E. Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grade III and IV gliomas. Neuro Oncol. 2020 2020 May 05. - PMC - PubMed
    1. Boffa D.J., Judson B.L., Billingsley K.G., Galetta D., Fontanezl P., Odermatt C., Lindner K., Mitchell M.R., Henderson C.H., Carafeno T., Pinto J., Wagner J., Ancuta M., Beley P., Turner A.L., Banack T., Laurans M.S., Johnson D.C., Yoo P., Morton J.M., Zurich H., Davis K., Ahuja N. Pandemic recovery using a Covid-minimal cancer surgery pathway. Ann. Thorac. Surg. 2020 doi: 10.1016/j.athoracsur.2020.05.003. 10.1016/j.athoracsur.2020.05.003. - DOI - PMC - PubMed
    1. Bogani G., Casarin J., Pinelli C., Di Donato V., Bosio S., Ruisi S., Brusadelli C., Guerrisi R., Sarpietro G., Ditto A., Ghezzi F., Raspagliesi F. Management of patients with ovarian cancer in the COVID-19 era. J. Surg. Oncol. 2020 May 31. - PMC - PubMed
    1. Boulware D.R., Pullen M.F., Bangdiwala A.S., Pastick K.A., Lofgren S.M., Okafor E.C., Skipper C.P., Nascene A.A., Nicol M.R., Abassi M., Engen N.W., Cheng M.P., LaBar D., Lother S.A., MacKenzie L.J., Drobot G., Marten N., Zarychanski R., Kelly L.E., Schwartz I.S., McDonald E.G., Rajasingham R., Lee T.C., Hullsiek K.H. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2016638. 2020 Jun 3. - DOI - PMC - PubMed

Publication types

MeSH terms